Pub Date : 2023-01-01Epub Date: 2022-10-26DOI: 10.4046/trd.2022.0087
EunMi Mun, Jaehyuk Cho
Everyone is aware that air and environmental pollutants are harmful to health. Among them, indoor air quality directly affects physical health, such as respiratory rather than outdoor air. However, studies that have examined the correlation between environmental and health information have been conducted with public data targeting large cohorts, and studies with real-time data analysis are insufficient. Therefore, this research explores the research with an indoor air quality monitoring (AQM) system based on developing environmental detection sensors and the internet of things to collect, monitor, and analyze environmental and health data from various data sources in real-time. It explores the usage of wearable devices for health monitoring systems. In addition, the availability of big data and artificial intelligence analysis and prediction has increased, investigating algorithmic studies for accurate prediction of hazardous environments and health impacts. Regarding health effects, techniques to prevent respiratory and related diseases were reviewed.
{"title":"Review of Internet of Things-Based Artificial Intelligence Analysis Method through Real-Time Indoor Air Quality and Health Effect Monitoring: Focusing on Indoor Air Pollution That Are Harmful to the Respiratory Organ.","authors":"EunMi Mun, Jaehyuk Cho","doi":"10.4046/trd.2022.0087","DOIUrl":"10.4046/trd.2022.0087","url":null,"abstract":"<p><p>Everyone is aware that air and environmental pollutants are harmful to health. Among them, indoor air quality directly affects physical health, such as respiratory rather than outdoor air. However, studies that have examined the correlation between environmental and health information have been conducted with public data targeting large cohorts, and studies with real-time data analysis are insufficient. Therefore, this research explores the research with an indoor air quality monitoring (AQM) system based on developing environmental detection sensors and the internet of things to collect, monitor, and analyze environmental and health data from various data sources in real-time. It explores the usage of wearable devices for health monitoring systems. In addition, the availability of big data and artificial intelligence analysis and prediction has increased, investigating algorithmic studies for accurate prediction of hazardous environments and health impacts. Regarding health effects, techniques to prevent respiratory and related diseases were reviewed.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e4/26/trd-2022-0087.PMC9816487.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10867778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
It is identical to the Creative Commons Attribution NonCommercial License (http:// creativecommons.org/licenses/ by-nc/4.0/). Last year, a group of experts on chronic obstructive pulmonary disease (COPD) proposed an updated definition of COPD exacerbation. They reached a consensus on the new definition using a modified Delphi method and named it ‘the Rome Proposal’ (Table 1). As a correct definition of COPD exacerbation is necessary not only for clinical practice but also for healthcare decisions, the Rome Proposal was designed to overcome the shortcomings of the current definition of COPD exacerbation documented by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy. One of the shortcomings of the GOLD definition is that it relies only on subjective symptoms, which can be mimicked by pneumonia, heart failure, or pulmonary thromboembolism. In contrast, in the Rome Proposal, the experts suggested objective measurements of respiratory rate, heart rate, serum C-reactive protein, pulse oximetry, and arterial blood gas in addition to the symptoms. The Rome Proposal also suggests the evaluation of differential diagnosis and etiologic testing for airway insult and removes the term, “additional therapy” from the definition of COPD exacerbation. This is because an additional therapy may differ across COPD patients due to its availability and the preference of patients or physicians upon COPD exacerbation. However, a good definition should be concise, with the exclusion of non-essential components, and must be composed of two parts—genus (category of concept) and differentia (differentiating characteristics). A good definition of COPD exacerbation is fundamental for precise communication among healthcare professionals, patients, medical students, and even the general public. Considering the com-
{"title":"Definition of Chronic Obstructive Pulmonary Disease Exacerbation: The Essentials of the Rome Proposal.","authors":"Yeon-Mok Oh","doi":"10.4046/trd.2022.0119","DOIUrl":"https://doi.org/10.4046/trd.2022.0119","url":null,"abstract":"It is identical to the Creative Commons Attribution NonCommercial License (http:// creativecommons.org/licenses/ by-nc/4.0/). Last year, a group of experts on chronic obstructive pulmonary disease (COPD) proposed an updated definition of COPD exacerbation. They reached a consensus on the new definition using a modified Delphi method and named it ‘the Rome Proposal’ (Table 1). As a correct definition of COPD exacerbation is necessary not only for clinical practice but also for healthcare decisions, the Rome Proposal was designed to overcome the shortcomings of the current definition of COPD exacerbation documented by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy. One of the shortcomings of the GOLD definition is that it relies only on subjective symptoms, which can be mimicked by pneumonia, heart failure, or pulmonary thromboembolism. In contrast, in the Rome Proposal, the experts suggested objective measurements of respiratory rate, heart rate, serum C-reactive protein, pulse oximetry, and arterial blood gas in addition to the symptoms. The Rome Proposal also suggests the evaluation of differential diagnosis and etiologic testing for airway insult and removes the term, “additional therapy” from the definition of COPD exacerbation. This is because an additional therapy may differ across COPD patients due to its availability and the preference of patients or physicians upon COPD exacerbation. However, a good definition should be concise, with the exclusion of non-essential components, and must be composed of two parts—genus (category of concept) and differentia (differentiating characteristics). A good definition of COPD exacerbation is fundamental for precise communication among healthcare professionals, patients, medical students, and even the general public. Considering the com-","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4c/2e/trd-2022-0119.PMC9816486.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10868330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Prosenjit Mukherjee, Mohanchandra Mandal, Antonio M Esquinas
Prosenjit Mukherjee, Mohanchandra Mandal, Antonio M. Esquinas. Authors: 1. Dr.Prosenjit Mukherjee (MD) Associate Professor, Department of Anaesthesiology, Institute of Post Graduate Medical Education & Research, Kolkata, West Bengal, India. Email: docposhu@gmail.com Orcid Id: 0000-0002-6228-3769 2. Dr.Mohanchandra Mandal (MD) Professor, Department of Anaesthesiology Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India. Email: drmcmandal@gmail.com Orcid ID: 0000-0003-4183-993X 3. Dr.Antonio M. Esquinas(MD, PhD, FCCP, FNIV, FAARC) Critical Care Specialist and Staff Physician, Intensive Care Unit, Hospital Morales, Meseguer, Murcia, Spain. Email:antmesquinas@gmail.com Orcid ID: 0000-0003-0571-2050
{"title":"Early Use of High Flow Nasal Cannula in Postextubation Period: Can It Reduce Reintubation Rate?","authors":"Prosenjit Mukherjee, Mohanchandra Mandal, Antonio M Esquinas","doi":"10.4046/trd.2022.0113","DOIUrl":"https://doi.org/10.4046/trd.2022.0113","url":null,"abstract":"Prosenjit Mukherjee, Mohanchandra Mandal, Antonio M. Esquinas. Authors: 1. Dr.Prosenjit Mukherjee (MD) Associate Professor, Department of Anaesthesiology, Institute of Post Graduate Medical Education & Research, Kolkata, West Bengal, India. Email: docposhu@gmail.com Orcid Id: 0000-0002-6228-3769 2. Dr.Mohanchandra Mandal (MD) Professor, Department of Anaesthesiology Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India. Email: drmcmandal@gmail.com Orcid ID: 0000-0003-4183-993X 3. Dr.Antonio M. Esquinas(MD, PhD, FCCP, FNIV, FAARC) Critical Care Specialist and Staff Physician, Intensive Care Unit, Hospital Morales, Meseguer, Murcia, Spain. Email:antmesquinas@gmail.com Orcid ID: 0000-0003-0571-2050","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/eb/d5/trd-2022-0113.PMC9816493.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10510615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Captive.","authors":"Brian Robert Smith","doi":"10.4046/trd.2022.0130","DOIUrl":"https://doi.org/10.4046/trd.2022.0130","url":null,"abstract":"","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/22/2c/trd-2022-0130.PMC9816491.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10867769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Address for correspondence Young Seok Lee, M.D., Ph.D. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, 148 Gurodong-ro, Guro-gu, Seoul 08308, Republic of Korea Phone 82-2-2626-3256 Fax 82-2-2626-1166 E-mail avonlea76@korea.ac.kr Received Dec. 8, 2022 Revised Dec. 9, 2022 Accepted Dec. 9, 2022 Published online Dec. 12, 2022
{"title":"Early Use of High-Flow Nasal Cannula in Postextubation Period: Can It Reduce Reintubation Rate? Authors' Reply.","authors":"Jae Kyeom Sim, Young Seok Lee","doi":"10.4046/trd.2022.0161","DOIUrl":"https://doi.org/10.4046/trd.2022.0161","url":null,"abstract":"Address for correspondence Young Seok Lee, M.D., Ph.D. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, 148 Gurodong-ro, Guro-gu, Seoul 08308, Republic of Korea Phone 82-2-2626-3256 Fax 82-2-2626-1166 E-mail avonlea76@korea.ac.kr Received Dec. 8, 2022 Revised Dec. 9, 2022 Accepted Dec. 9, 2022 Published online Dec. 12, 2022","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f8/e5/trd-2022-0161.PMC9816485.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10509613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01Epub Date: 2022-10-05DOI: 10.4046/trd.2022.0066
Eun Ki Chung, Seung Hyun Yong, Eun Hye Lee, Eun Young Kim, Yoon Soo Chang, Sang Hoon Lee
Lung cancer ranks first in cancer mortality in Korea and cancer incidence in Korean men. More than half of Korean lung cancer patients undergo chemotherapy, including adjuvant therapy. Cytotoxic agents, targeted therapy, and immune checkpoint inhibitors are used in chemotherapy according to the biopsy and genetic test results. Among chemotherapy, the one that has developed rapidly is targeted therapy. The National Comprehensive Cancer Network (NCCN) guidelines have been updated recently for targeted therapy of multiple gene mutations, and targeted therapy is used not only for chemotherapy but also for adjuvant therapy. While previously targeted therapies have been developed for common genetic mutations, recently targeted therapies have been developed to overcome uncommon mutations or drug resistance that have occurred since previous targeted therapy. Therefore, this study describes recent, rapidly developing targeted therapies.
{"title":"New Targeted Therapy for Non-Small Cell Lung Cancer.","authors":"Eun Ki Chung, Seung Hyun Yong, Eun Hye Lee, Eun Young Kim, Yoon Soo Chang, Sang Hoon Lee","doi":"10.4046/trd.2022.0066","DOIUrl":"10.4046/trd.2022.0066","url":null,"abstract":"<p><p>Lung cancer ranks first in cancer mortality in Korea and cancer incidence in Korean men. More than half of Korean lung cancer patients undergo chemotherapy, including adjuvant therapy. Cytotoxic agents, targeted therapy, and immune checkpoint inhibitors are used in chemotherapy according to the biopsy and genetic test results. Among chemotherapy, the one that has developed rapidly is targeted therapy. The National Comprehensive Cancer Network (NCCN) guidelines have been updated recently for targeted therapy of multiple gene mutations, and targeted therapy is used not only for chemotherapy but also for adjuvant therapy. While previously targeted therapies have been developed for common genetic mutations, recently targeted therapies have been developed to overcome uncommon mutations or drug resistance that have occurred since previous targeted therapy. Therefore, this study describes recent, rapidly developing targeted therapies.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ab/c9/trd-2022-0066.PMC9816494.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10522204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
It is identical to the Creative Commons Attribution NonCommercial License (http:// creativecommons.org/licenses/ by-nc/4.0/). Sixty-two-year-old male presented with increasing cough, purulent sputum, and breathlessness for 3 days. Over the last 30 years, the patient has had a recurring cough with sputum, often interrupted by exacerbations, requiring multiple outpatient and emergency visits, and on several occasions, admissions for antibiotics, oxygen, and bronchodilator therapy. Clinical examination revealed tachypnoea with peripheral saturation of 91%, tachycardia, pallor, digital clubbing, with bilateral crackles, and wheeze on chest auscultation. Blood investigations and arterial blood gas analysis revealed anaemia and hypoxemia, respectively. Sputum microbiology, sweat chloride, and serum immunoglobulin profile were non-contributory. Chest radiograph showed bilateral lower zone cystic changes (yellow circles) with airspace opacities (white arrows) (Figure 1). A computed tomography scan of the chest revealed tracheomegaly (tracheal diameter 31.29 mm) with multiple tracheal and bronchial wall diverticula (red arrows), upper lobe emphysema (E), bilateral bronchiectasis (yellow arrows), and right lung consolidation (P) (Figure 2A, B). Flexible bronchoscopy confirmed multiple tracheal and bronchial wall diverticulosis (white arrows), with visible overlying atrophied longitudinal smooth muscle (black arrows), consistent with Mounier-Kuhn syndrome (Figure 2C). The bronchoalveolar lavage from the middle lobe grew Klebsiella pneumoniae. He was discharged after clinical and radiological results showed improvement following appropriate antibiotic, oxygen, and bronchodilator therapy. He continues having reasonable symptom control with regular home nebulized bronchodilator therapy and chest physiotherapy, and
{"title":"Mounier-Kuhn Syndrome.","authors":"Irfan Ismail Ayub, Krishnamoorthy Vengadakrishnan","doi":"10.4046/trd.2022.0123","DOIUrl":"https://doi.org/10.4046/trd.2022.0123","url":null,"abstract":"It is identical to the Creative Commons Attribution NonCommercial License (http:// creativecommons.org/licenses/ by-nc/4.0/). Sixty-two-year-old male presented with increasing cough, purulent sputum, and breathlessness for 3 days. Over the last 30 years, the patient has had a recurring cough with sputum, often interrupted by exacerbations, requiring multiple outpatient and emergency visits, and on several occasions, admissions for antibiotics, oxygen, and bronchodilator therapy. Clinical examination revealed tachypnoea with peripheral saturation of 91%, tachycardia, pallor, digital clubbing, with bilateral crackles, and wheeze on chest auscultation. Blood investigations and arterial blood gas analysis revealed anaemia and hypoxemia, respectively. Sputum microbiology, sweat chloride, and serum immunoglobulin profile were non-contributory. Chest radiograph showed bilateral lower zone cystic changes (yellow circles) with airspace opacities (white arrows) (Figure 1). A computed tomography scan of the chest revealed tracheomegaly (tracheal diameter 31.29 mm) with multiple tracheal and bronchial wall diverticula (red arrows), upper lobe emphysema (E), bilateral bronchiectasis (yellow arrows), and right lung consolidation (P) (Figure 2A, B). Flexible bronchoscopy confirmed multiple tracheal and bronchial wall diverticulosis (white arrows), with visible overlying atrophied longitudinal smooth muscle (black arrows), consistent with Mounier-Kuhn syndrome (Figure 2C). The bronchoalveolar lavage from the middle lobe grew Klebsiella pneumoniae. He was discharged after clinical and radiological results showed improvement following appropriate antibiotic, oxygen, and bronchodilator therapy. He continues having reasonable symptom control with regular home nebulized bronchodilator therapy and chest physiotherapy, and","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0e/c9/trd-2022-0123.PMC9816488.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9082301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Umeclidinium/vilanterol (UMEC/VI; ANORO ELLIPTA, GSK) is a commonly used dual bronchodilator. This study evaluated the safety and effectiveness of UMEC/VI in Korean patients with chronic obstructive pulmonary disease (COPD) over a 6-year period.
Methods: This was an open-label, multicentre, observational, post-marketing surveillance study. A total of 3,375 patients were enrolled consecutively in 52 hospitals, by 53 physicians, between July 2014 and July 2020. Patients who were administered UMEC/VI (fixed-dose 62.5 μg/25 μg) at least once and were monitored for safety and effectiveness were included in the analysis. Incidence and severity of adverse events (AEs) reported after administrating at least one dose of UMEC/VI were monitored, including unexpected adverse events (UAEs) and adverse drug reactions (ADRs). Effectiveness of UMEC/VI after 24 weeks of administration was also assessed using physician's evaluation (effective, ineffective/no change, worsening, indeterminable) and lung function improvement.
Results: Of 3,375 patients, 3,086 were included in the safety assessment group (mean age±standard deviation: 69.76±8.80 years; 85.9% male [n=2,652]; 73.1% aged ≥65 years [n=2,255]). The overall incidence of AEs was 28.8% (n=890), of which 2.2% (n=67) were ADRs. Serious AEs and UAEs were reported in 181 (5.9%) and 665 (21.6%) patients, respectively, and two patients (<0.1%) reported unexpected severe ADR. Of the 903/3,086 patients analysed for effectiveness, most (82.8%, n=748) showed overall disease improvement after UMEC/VI treatment.
Conclusion: This study confirmed UMEC/VI administered to Korean patients according to the prescribing information was well-tolerated and can be considered an effective option for COPD treatment.
{"title":"An Open-Label, Multicentre, Observational, Post-Marketing Study to Monitor the Safety and Effectiveness of Umeclidinium/Vilanterol in Korean Patients.","authors":"Eun-Yeong Cho, Jung-Eun Cho, Eun-Bin Lee, Seung Soo Yoo, Jung Hyun Chang","doi":"10.4046/trd.2022.0055","DOIUrl":"https://doi.org/10.4046/trd.2022.0055","url":null,"abstract":"<p><strong>Background: </strong>Umeclidinium/vilanterol (UMEC/VI; ANORO ELLIPTA, GSK) is a commonly used dual bronchodilator. This study evaluated the safety and effectiveness of UMEC/VI in Korean patients with chronic obstructive pulmonary disease (COPD) over a 6-year period.</p><p><strong>Methods: </strong>This was an open-label, multicentre, observational, post-marketing surveillance study. A total of 3,375 patients were enrolled consecutively in 52 hospitals, by 53 physicians, between July 2014 and July 2020. Patients who were administered UMEC/VI (fixed-dose 62.5 μg/25 μg) at least once and were monitored for safety and effectiveness were included in the analysis. Incidence and severity of adverse events (AEs) reported after administrating at least one dose of UMEC/VI were monitored, including unexpected adverse events (UAEs) and adverse drug reactions (ADRs). Effectiveness of UMEC/VI after 24 weeks of administration was also assessed using physician's evaluation (effective, ineffective/no change, worsening, indeterminable) and lung function improvement.</p><p><strong>Results: </strong>Of 3,375 patients, 3,086 were included in the safety assessment group (mean age±standard deviation: 69.76±8.80 years; 85.9% male [n=2,652]; 73.1% aged ≥65 years [n=2,255]). The overall incidence of AEs was 28.8% (n=890), of which 2.2% (n=67) were ADRs. Serious AEs and UAEs were reported in 181 (5.9%) and 665 (21.6%) patients, respectively, and two patients (<0.1%) reported unexpected severe ADR. Of the 903/3,086 patients analysed for effectiveness, most (82.8%, n=748) showed overall disease improvement after UMEC/VI treatment.</p><p><strong>Conclusion: </strong>This study confirmed UMEC/VI administered to Korean patients according to the prescribing information was well-tolerated and can be considered an effective option for COPD treatment.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3f/40/trd-2022-0055.PMC9816489.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10516492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Keun Ju Kim, Seung-Hwan Oh, Doosoo Jeon, Chulhun L Chang
Background: There is a global increase in isolation of nontuberculous mycobacteria (NTM). The aim of the study was to analyze longitudinal trends of NTM identification and pattern of antimicrobial susceptibility testing.
Methods: NTM recovery rates, distribution of NTM species identification, and antimicrobial susceptibility pattern of NTM at Pusan National University Yangsan Hospital between January 2016 and December 2020 were retrospectively analyzed.
Results: A total of 52,456 specimens from 21,264 patients were submitted for mycobacterial culture, of which 2,521 from 1,410 patients were NTM positive over five years (January 2016 to December 2020). NTM isolation showed an increasing trend from 2016 to 2020 (p<0.001, test for trend) mainly caused by Mycobacterium avium complex. The vast majority of M. avium complex were susceptible to key agents clarithromycin and amikacin. For Mycobacterium kansasii, resistance to rifampin and clarithromycin is rare. Amikacin was the most effective drug against Mycobacterium abscessus subspecies abscessus and Mycobacterium subspecies massiliense. Most of M. subspecies massiliense were susceptible to clarithromycin, while the majority of M. abscessus subspecies abscessus were resistant to clarithromycin (p<0.001).
Conclusion: There was an increasing trend of NTM isolation in our hospital. Resistance to key drugs was uncommon for most NTM species except for M. abscessus subspecies abscessus against clarithromycin.
{"title":"Isolation and Antimicrobial Susceptibility of Nontuberculous Mycobacteria in a Tertiary Hospital in Korea, 2016 to 2020.","authors":"Keun Ju Kim, Seung-Hwan Oh, Doosoo Jeon, Chulhun L Chang","doi":"10.4046/trd.2022.0115","DOIUrl":"https://doi.org/10.4046/trd.2022.0115","url":null,"abstract":"<p><strong>Background: </strong>There is a global increase in isolation of nontuberculous mycobacteria (NTM). The aim of the study was to analyze longitudinal trends of NTM identification and pattern of antimicrobial susceptibility testing.</p><p><strong>Methods: </strong>NTM recovery rates, distribution of NTM species identification, and antimicrobial susceptibility pattern of NTM at Pusan National University Yangsan Hospital between January 2016 and December 2020 were retrospectively analyzed.</p><p><strong>Results: </strong>A total of 52,456 specimens from 21,264 patients were submitted for mycobacterial culture, of which 2,521 from 1,410 patients were NTM positive over five years (January 2016 to December 2020). NTM isolation showed an increasing trend from 2016 to 2020 (p<0.001, test for trend) mainly caused by Mycobacterium avium complex. The vast majority of M. avium complex were susceptible to key agents clarithromycin and amikacin. For Mycobacterium kansasii, resistance to rifampin and clarithromycin is rare. Amikacin was the most effective drug against Mycobacterium abscessus subspecies abscessus and Mycobacterium subspecies massiliense. Most of M. subspecies massiliense were susceptible to clarithromycin, while the majority of M. abscessus subspecies abscessus were resistant to clarithromycin (p<0.001).</p><p><strong>Conclusion: </strong>There was an increasing trend of NTM isolation in our hospital. Resistance to key drugs was uncommon for most NTM species except for M. abscessus subspecies abscessus against clarithromycin.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/57/5a/trd-2022-0115.PMC9816495.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10516995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Tuberculosis: Republic of Korea, 2021.","authors":"Jinsoo Min, Hyung Woo Kim, Ju Sang Kim","doi":"10.4046/trd.2022.0111","DOIUrl":"https://doi.org/10.4046/trd.2022.0111","url":null,"abstract":"","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c7/28/trd-2022-0111.PMC9816490.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9081270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}